This press release contains forward-looking statements about Sangamo`s current expectations. These forward-looking statements include statements regarding the potential for development, regulatory approvals for and marketing SB-525 as a safe and effective therapy for the treatment of hemophilia A, the potential long-term sustainability of SB-525 treatment, the expected plans and timelines for Phase 3 clinical trials and the exchange of additional clinical data, sangamo potential, milestone payment and royalties in its collaboration with Pfizer, timing of these payments and royalties and other non-historical statements. These statements are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict. Sangamo`s actual results may differ materially and negatively from the results expressed. It cannot be certain that Sangamo will receive additional milestones or royalties as part of the Pfizer collaboration. Factors that could lead to different actual results include risks and uncertainties related to the evolution of the COVID-19 pandemic and its impact on the global business environment, health systems, activities and activities of Sangamo and Pfizer; The research and development process uncertain timing and unpredictable clinical trial outcomes, including whether definitive clinical data will confirm the safety and efficacy of SB-525; The unpredictability of the authorisation process for product applicants in several regulatory authorities; Manufacturing products and candidates Marketing licensed products; The technological development potential that drives the technologies used by Sangamo and Pfizer away from the SB-525; Pfizer`s potential to terminate the SB-525 program or to terminate or sever its cooperation agreement with Sangamo; and Sangamo`s potential not to realize the expected benefits of working with Pfizer. These risks and uncertainties are described in more detail in Sangamo`s notifications to the U.S. Securities and Exchange Commission, including the latest Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and the Annual Report on Form 10-K for the year ended December 31, 2019. The information contained in this press release is as of October 7, 2020 and Sangamo undertakes no commitment to update any forward-looking statements contained in this press release, except as required by law. NEW YORK (Reuters) – U.S. drug maker Pfizer Inc. on Wednesday reached an agreement with Sangamo Therapeutics Inc. on the rights to its gene therapy programs to treat the rare blood clotting disorder, hemophilia A, under which Pfizer will pay $70 million in advance.
Sangamo Therapeutics` mission is to transform groundbreaking science into genomic drugs, with the potential to transform patients` lives through gene therapy, ex-gene cell therapy and in vivo genome treatment and genetic gene management. For more information about Sangamo, see www.sangamo.com. Under the cooperation agreement, Sangamo will receive a $70 million down payment from Pfizer. Sangamo will be responsible for the completion of the sB-525 phase 1/2 clinical trial and certain manufacturing activities.